154 results about "Food intake" patented technology

The invention relates to the field of biological medicine, in particular to application of hispidulin in preparation of a lipid de novo synthesis inhibitor or a metabolism-related fatty liver disease treatment or prevention product. The hispidulin disclosed by the invention has a chemical structure as shown in a formula (I). The hispidulin in the invention reverses liver cell lipid droplet excessive infiltration induced by high-dose fructose in a dose-dependent manner; furthermore, the hispidulin dose-dependent ameliorating obesity signs in HFD-induced MAFLD model mice, including liver weight, body weight, blood lipid level, liver fat content, and insulin resistance, without significantly reducing food intake.

The invention provides a captive panda oestrus starting prediction method and system based on machine learning, and relates to the technical field of panda breeding, and the method comprises the steps: obtaining original data; isomerous data stream synchronization is carried out according to the original data, and a synchronized spatio-temporal data matrix is obtained; performing nonlinear interaction relation modeling according to the synchronized spatio-temporal data matrix to construct a spatio-temporal dependency relation graph; performing environment constraint feature dimension reduction according to the space-time dependency graph to obtain a low-dimensional state representation vector; performing oestrus state transition probability calculation according to the low-dimensional state representation vector to generate a probability evolution trajectory; and according to the probability evolution trajectory, turning point identification is carried out, and an estrus starting moment prediction value is output. Through collaborative inflection point detection of progesterone gradient characteristics and an ingestion mutation mode in the probability evolution trajectory, an estrus starting moment prediction value is accurately output, and finally the biological interpretability of estrus critical state evolution of captive pandas is improved.

Techniques disclosed herein relate generally to monitoring and tracking food intake events or other behaviors. In some examples, the techniques involve detecting, based on at least one of user input or sensor input from a first set of one or more sensors, a start of a food intake event; activating, in response to detecting the start of the food intake event, a second set of one or more sensors for tracking the food intake event; and determining, based on at least sensor data from the second set of one or more sensors, one or more event-specific parameters for the food intake event.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

A system includes a processor that collects data representing activity levels, sleep patterns, and food intake from an information collection device attached to a dog, transmits the collected data to an analysis server, wherein the analysis server inputs the collected data into a generative artificial intelligence model and analyzes the data, transmits analysis results to a terminal and notifies a user, receives user input regarding questions or symptoms of the dog and generates advice using the generative artificial intelligence model, transmits the generated advice to the terminal for display to the user, and provides online consultation reservation with a veterinarian.

The images related to this design are used, for example, to monitor, display, or track measurement data such as blood glucose levels, as well as exercise, insulin administration, and food intake. These images can be operated by tapping, pressing, swiping, or scrolling the display screen, or via other devices associated with the display device.

The present application relates to the technical field of food intake monitoring system, in particular to an intelligent energy cup food intake monitoring system and method thereof, a multi-sensor data acquisition module; a data preprocessing module electrically connected with the multi-sensor data acquisition module; an AI analysis module data connected with the data preprocessing module; according to the liquid type and the eating behavior, combined with the preset health standard, the real-time food intake of the user is calculated; based on the real-time food intake and the user historical data, the blood glucose curve of the user is predicted; an intelligent intervention module is signal connected with the AI analysis module, whether the preset health threshold is exceeded is judged; when the judgment result exceeds the health threshold, the corresponding intervention instruction is generated; a feedback execution module is control connected with the intelligent intervention module, a data storage and communication module is data connected with the multi-sensor data acquisition module, the AI analysis module and the intelligent intervention module respectively; the data is uploaded to the remote server through the wireless network, the cloud backup and analysis of the data are realized.

The present application relates to a kind of traditional Chinese medicine composition for treating pediatric anorexia, the traditional Chinese medicine composition is made of the following weight parts of raw medicinal materials: 7-11 parts of Taizishen, 7-11 parts of Cangzhu, 7-11 parts of Fuling, 7-11 parts of Huoxiang, 7-11 parts of Gegen, 7-11 parts of Qingpi, 6-13 parts of Laiqiezi, 4-8 parts of Lianqiao, 7-11 parts of Sanleng, 7-11 parts of Shanzha.The present application also provides the use of traditional Chinese medicine composition for pediatric anorexia.The present application uses several drugs together, which is integrated with invigorating spleen, transporting spleen and activating spleen, so that the spleen is healthy, the spleen and stomach qi movement is appropriate, and the human body qi movement is adjusted, so that the whole body qi movement is operated, the qi movement is operated, the five internal organs are harmonious, and the whole prescription plays the effect of invigorating spleen and transporting.The total effective rate and the improvement of TCM syndrome score of the traditional Chinese medicine composition of the present application are better than those of the control group, especially in improving the symptoms of anorexia, reduced food intake and other symptoms such as salivation, belching, hiccups, nausea and other symptoms.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing visceral fat in a mammal is provided where the composition comprises an effective amount of Cissus quadrangularis provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards5 to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

The utility model discloses nutrition matching tableware with a quantitative matching function, which belongs to the technical field of tableware processing and comprises a meal box, a box cover is hinged to the top surface of the meal box through a hinge, the meal box and the box cover are clamped through a lock catch, and an adjusting structure for quantitative matching is movably mounted in the meal box. The dinner plate is divided into the dish groove, the staple food groove and the porridge and soup groove so that different types of food can be clearly separated, the sanitation and freshness of the food can be kept, cross contamination possibly caused by food mixing can be reduced, the adjusting structure is arranged, and therefore the food can be conveniently and rapidly heated, and the service life of the dinner plate can be prolonged. The adjusting plate is flexibly controlled to drive the adjusting box to move along the sawtooth plate, the inner depth of the dinner plate is effectively changed, personalized catering is achieved, the food intake is accurately controlled, the inner capacity of the dinner plate is further changed in cooperation with the movable partition plate, the food amount of each meal is strictly controlled, and the body burden of a patient is prevented from being aggravated due to excessive food intake.

The application provides application of a Baoji oral liquid composition in preparation of a functional dyspepsia medicine, and relates to the technical field of medicines. The application is based on the Baoji oral liquid, and it is found that the Baoji oral liquid has a remarkable effect on treating functional dyspepsia, especially cisplatin-induced functional dyspepsia. Specifically, the Baoji oral liquid can rapidly restore body weight, significantly improve body weight gain, steadily promote food intake, significantly improve gastric emptying rate and intestinal propulsion rate, protect the gastric mucosa layer, reduce inflammatory cell infiltration, repair the mucosa layer and muscle layer, improve the expression of serum gastrin and motilin, and improve the expression level of IL-4 in the gastric tissue and reduce the expression level of IL-1beta. The Baoji oral liquid has remarkable efficacy when applied in preparation of a functional dyspepsia medicine.

The objective is to provide a diversity assessment device, a diversity assessment method, and a diversity assessment program that can assess food diversity while considering nutrient diversity by evaluating the diversity of ingested foods based on clusters that classify foods. [Solution] Based on food component data, a food classification is set by classifying the target specified foods according to nutrients using a clustering method, data on the intake status of specified foods included in a meal classified according to the food classification is obtained, and a dietary diversity score is calculated for the specified food intake status data.

The invention belongs to the technical field of biological medicines, and particularly relates to a composite active polypeptide composition with a weight losing effect and a preparation method thereof. The composite active polypeptide composition comprises NT analogue polypeptide ELP3, mulberry leaf polypeptide, balsam pear polypeptide, sea cucumber polypeptide and oyster peptide; the amino acid sequence of the NT analogue polypeptide ELP3 is as shown in SEQ ID NO. 1. According to the present invention, the artificial peptide fragment AYYKSQWLVNGEGTP is added to the end of the wild type NT, such that the gastric acid secretion can be inhibited, and the activity of the alpha-amylase can be significantly inhibited; the NT analogue polypeptide ELP3 and various polypeptide components are matched to achieve a synergistic effect, so that the blood fat metabolism condition of obese mice can be effectively improved, and the fat weight of the mice is reduced; meanwhile, the food intake of the mice can be remarkably inhibited, so that the purpose of reducing the weight of the mice is achieved, and a good weight-losing effect is achieved.

The Endoscopic Adjustable Gastric Barrier represents a groundbreaking innovation in the management of obesity, offering a unique, minimal invasive approach without the complications and limitation of other currently available interventional managements., this revolutionary technique works by dividing the stomach into a smaller, tube-like space for food, without altering the stomach's natural anatomy or functions. This preserves the stomach's function to produce hormones and digestive juices, while effectively reducing food intake hence significant weight loss. What makes this innovation (EAGB) unique is its adjustability and reversibility, and when ideal weight is achieved it can be removed endoscopically. It is secured to the stomach by clips with minimal injury and without risk of necrosis and leak. Additionally, all endoscopic and laparoscopic interventions are possible as normal population.

An object of the system according to the embodiment is to check a health condition by comprehensively analyzing daily health data and video data.SOLUTION: A system includes a data storage part, a health condition check part, a video recording part, and a motion analysis part. The data storage unit stores data of a meal amount, an exercise amount, and excretion. The health condition check unit checks a health condition using the data accumulated by the data accumulation unit. The video recording unit records daily video data. The motion analysis unit analyzes the video data recorded by the video recording unit to detect a change in motion or an injury.SELECTED DRAWING: Figure 1

The invention relates to the technical field of milk intake monitoring, and discloses an automatic monitoring and recording device for milk intake. Which comprises a feeding bottle body and is characterized in that a bottle cap is installed at the top of the feeding bottle body, a measuring assembly is arranged on the outer side of the feeding bottle body and comprises a first rubber pad and a second rubber pad which are fixed to the inner wall of the bottle cap, and a soft tape is installed between the first rubber pad and the second rubber pad; by arranging the monitoring assembly, the milk intake can be conveniently and automatically monitored, the feeding time or the feeding amount of each time can be recorded in real time, errors of a traditional measuring method are avoided, accurate milk intake information is provided for parents and medical staff, the diet law of a baby can be analyzed, and the feeding efficiency of the baby is improved. By arranging the measuring assembly, the soft measuring tape can be conveniently stored in the bottle cap, the soft measuring tape can be properly stored and kept clean and tidy, the bottle cap can be conveniently used next time, meanwhile, carrying and storing are convenient, and convenience is improved.

A Lacticaseibacillus rhamnosus MBP01 and a combination thereof for preventing and treating irritable bowel syndrome are provided, which relates to the technical field of microorganism. A deposit number of the Lacticaseibacillus rhamnosus MBP01 is GDMCC NO: 64725. The MBP01 can improve a weight loss trend of IBS model mice, increase food intake and feces water content, alleviate colon tissue damage, downregulate expression levels of IL-1β, TNF-α, PAR-2, and serum CORT and increase an expression level of IL-10. MBP01 with a high concentration can improve an expression level of OCC. Therefore, MBP01 has a certain positive regulatory effect on the intestinal function of IBS model mice and can effectively prevent and treat irritable bowel syndrome.

The invention provides a dietary fiber composition capable of reducing calorie intake and slowing down digestion speed and a preparation method thereof, and belongs to the technical field of weight control. The feed additive is prepared from the following raw materials in parts by weight: 18-20 parts of sodium carboxymethyl cellulose, 1-2 parts of lecithin, 15-18 parts of modified konjac glucomannan, 4-8 parts of L-carnitine, 4-8 parts of a white kidney bean extract, 1-2 parts of chlorogenic acid and 3-5 parts of probiotics. The dietary fiber composition capable of reducing calorie intake and slowing down digestion speed, prepared by the invention, regulates fat metabolism in a targeted manner through multiple metabolism, reduces calorie intake, slows down digestion speed, improves glucose metabolism in a body, improves calorie consumption of the body, reduces fat hoarding, improves satiety, reduces food intake, prolongs the duration time of satiety, and has the efficacy of reducing calorie intake and slowing down digestion speed. Therefore, a good body weight control effect is achieved, and wide application prospects are achieved.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

The invention discloses carnitine grafted polyvinyl alcohol cross-linked hydrogel and a preparation method and application thereof, and belongs to the technical field of food, health care products or medical instruments.The carnitine grafted polyvinyl alcohol cross-linked hydrogel is obtained by grafting L-carnitine with polyvinyl alcohol in an acid environment and then conducting cross-linking through polycarboxylic acid. The preparation process does not use organic solvents, and is simple, economical and convenient. The grafting rate of the L-carnitine grafted polyvinyl alcohol is 1%-30%, and the swelling multiple of the carnitine grafted polyvinyl alcohol cross-linked hydrogel is 50-150 times when the carnitine grafted polyvinyl alcohol cross-linked hydrogel reaches swelling equilibrium in an acidic aqueous solution with the pH value of 2. The carnitine grafted polyvinyl alcohol cross-linked hydrogel disclosed by the invention is large in water absorption expansion times under an acidic condition, increases the volume occupying the stomach to provide satiety and reduces food intake, is limited in water absorption times or degraded and collapsed under a neutral / alkaline condition, is beneficial to being discharged out of a body, can be used for preparing weight-losing products, assists in controlling diet, and has a good market prospect. The effects of preventing or assisting in treating obesity and diseases caused by obesity and the like are achieved.

The invention discloses a method for evaluating spice regulation satiety based on animal behavioristics, which comprises the following steps of: establishing an appetite intervention model (intragastric spices or medicines), and adopting a modified elevated cross labyrinth device (comprising a detachable trough and a sensor); synchronously recording the incubation period T of the experimental subject in contact with the food for the first time, the number F of times of food area exploration and the food intake I, and calculating the correlation coefficient r of the behavior parameters and the food intake through a Pearson correlation coefficient formula. When rgt; and when 0.6, judging that the behavior change can reflect the satiety state. The method realizes multi-dimensional parameter cross validation of appetite evaluation, and is suitable for functional food and medicine development.

The invention relates to an efficient energy supply type laboratory mouse feed which comprises the following components in percentage by weight: 20-40% of corn, 10-30% of wheat, 1-5% of wheat middling, 4-10% of soybean meal, 2-8% of fish meal, 2-6% of chicken meal, 1-10% of soybean hull, 1-5% of soybean oil, 1-5% of lard, 0.5-2% of stone powder, 0.5-1.5% of calcium hydrophosphate, 2-5% of premix, 1-5% of MCT microcapsule powder and 0.5-2% of glutamine. The stability of MCT is improved through a microencapsulation method, the activity of glutamine is reserved through an embedding method, the synergistic effect of MCT microcapsule powder and glutamine is utilized, meanwhile, lard oil and fat raw materials are added, high-temperature steam is used for curing materials in the production process, the fragrance of the feed is further improved, the palatability of the feed is jointly improved, the food intake of laboratory mice is not affected, and the production cost is reduced. The utilization efficiency of the feed is improved; the experimental mouse feed can reduce body fat and improve blood lipid level, can effectively prolong exhaustion time of mice, and is suitable for cultivation and maintenance of special experimental animals such as intestinal injury models and immunodeficiency models.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative or its pharmaceutically acceptable salt, or its tautomer, meso compound, racemic compound, enantiomer, diastereomer, or pharmaceutical composition thereof as an active ingredient in the preparation of drugs for the prevention or treatment of obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative of this invention has significant therapeutic effects on obesity and related metabolic diseases. In obese mice induced by a high-fat diet and high-fructose water intake, gavage administration for 6 weeks showed that, compared with the high-fat control group, it inhibited more than 70% of the mice's weight gain, with no significant difference in food intake and water intake, demonstrating good clinical application prospects.

The present invention relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has the effects of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis and reducing triglyceride levels.

An integrated weight management system comprising a biocompatible intraoral device and personalized software is disclosed. The device, configured for insertion into the user's mouth, creates a separation between the tongue and teeth causing the stomatognathic system, limiting hunger cues associated with food anticipation. Sensors coupled to the device detect its removal and insertion, enabling the system to track adherence to meal plans and weight loss progress. The software utilizes machine learning algorithms to generate personalized meal plans, food intake timing, nutrition education, and exercise routines based on user preferences, dietary restrictions, and weight loss goals. The system analyzes user data to provide progress reports, adjust meal plans, and send alerts to promote accountability and compliance. This comprehensive approach addresses both physiological and psychological aspects of weight management, offering a novel and effective solution for achieving and maintaining a healthy weight.

The present invention provides novel compounds that are peptide hormone analogs and are useful for treating disorders such as diabetes and obesity.The compounds of the general sequence listed herein have tailored profiles of potency at the GIP receptor.Regarding in vivo properties, administration of exemplary peptides of the present invention has been shown to result in improved weight loss in animal models.Preferred compounds achieve this without significantly reducing food intake.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing fasting blood glucose in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.